Drug control of reverse cholesterol transport

Area of Science:

• Cardiovascular Medicine
• Metabolic Research
• Pharmacology

Background:

• Reverse cholesterol transport (RCT) facilitates the removal of excess cholesterol from peripheral tissues to the liver.
• High-density lipoproteins (HDL) are central to RCT, and higher plasma HDL levels correlate inversely with atherosclerosis.
• Targeting RCT presents a potential therapeutic strategy for preventing and treating arterial diseases.

Purpose of the Study:

• To explore the potential of stimulating reverse cholesterol transport for managing atherosclerosis.
• To review agents and strategies that enhance RCT, including pharmacological interventions and HDL level modulation.

Main Methods:

• Review of existing literature on reverse cholesterol transport and its role in atherosclerosis.
• Analysis of the effects of probucol on cholesteryl ester transfer protein activity and HDL composition.
• Examination of studies involving exogenous HDL supplementation and endogenous HDL overexpression in animal models.

Main Results:

• Probucol was identified as an agent that significantly impacts RCT by modulating cholesteryl ester transfer protein and HDL subfractions.
• Animal studies demonstrated that increasing plasma HDL levels, through supplementation or overexpression, aids in atherosclerosis regression or halting progression.
• These findings highlight the therapeutic potential of enhancing cholesterol removal from arterial walls.

Conclusions:

• Stimulating reverse cholesterol transport is a promising avenue for novel atherosclerosis treatments.
• Combining established lipid-lowering strategies with methods to enhance RCT could offer a more comprehensive approach to arterial disease management.
• Further research into RCT modulation is warranted to develop effective clinical interventions.